(Q34313688)

1 August 2017

Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia (English)

1 reference

1 August 2017

0 references

0 references

1 reference

1 reference

Edith Pomarol-Clotet

3

0 references

Peter Mckenna

Peter McKenna

4

0 references

Luke Clark

Luke Clark

2

0 references

Barbara J. Sahakian

Barbara J Sahakian

6

0 references

Trevor W. Robbins

Trevor W Robbins

5

0 references

author name string

Danielle C Turner

1

1 reference

PubMed ID

15085092

1 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

1 August 2017

Neuropsychopharmacology

1 reference

1 August 2017

29

1 reference

1 August 2017

7

1 reference

1 August 2017

1363-1373

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300457

1 August 2017

0 references

cites work

Neurocognitive and social functioning in schizophrenia and other diagnoses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Partial improvement in negative schizophrenic symptoms after amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Acts of control in schizophrenia: dissociating the components of inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: a helicopter simulator study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

The use of psychostimulants in general psychiatry. A reconsideration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Cognitive impairment as a target for pharmacological treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Study of the addictive potential of modafinil in naive and cocaine-experienced rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Effects of methylphenidate on spatial working memory and planning in healthy young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

21 January 2018

Varieties of impulsivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Wisconsin Card Sorting Test performance in schizophrenia: the role of working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Stability and course of neuropsychological deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Executive function in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Medicine. What are the right targets for psychopharmacology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Modafinil increases histamine release in the anterior hypothalamus of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Is psychosis exacerbated by modafinil?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Response inhibition in AD/HD, CD, comorbid AD/HD + CD, anxious, and control children: a meta-analysis of studies with the stop task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Planning and spatial working memory following frontal lobe lesions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Neuropsychological and olfactory dysfunction in schizophrenia: relationship of frontal syndromes to syndromes of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Cognitive functioning in schizophrenia: implications for psychiatric rehabilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

The involvement of orbitofrontal cerebrum in cognitive tasks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Cognitive impairment patterns in schizophrenia and affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Cognitive enhancing effects of modafinil in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Relative lack of cognitive effects of methylphenidate in elderly male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

The prevalence and stability of an executive processing deficit, response inhibition, in people with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

The effects of neurocognitive remediation on executive processing in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Are the effects of cognitive remediation therapy (CRT) durable? Results from an exploratory trial in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

A cognitive model of the positive symptoms of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

Neuropsychological evidence for frontostriatal dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

The use of analogue scales in rating subjective feelings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

Cognition in schizophrenia: from basic science to clinical treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

Psychomotor slowing and planning deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

fMRI and cognitive dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

Hypothalamic arousal regions are activated during modafinil-induced wakefulness.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

The cost of cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

Dopaminergic role in stimulant-induced wakefulness.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300457

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300457

1 reference

PubMed ID

15085092

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

15085092